FATE PEER ANALYSIS

Fate Therapeutics Inc — metric-by-metric comparison with peers and the industry median

FATEFate Therapeutics Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

FATEIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	FATE	MSB	TLX	RTALB	Ind. Median
P/E	—	—	—	4.89	17.91
P/B	1.95	—	6.37	0.61●	3.51
EV/EBITDA	—	—	120.14	74.61●	14.82
P/S	55.49	31.61	3.24●	6.67	10.89

Financial Health
Metric	FATE	MSB	TLX	RTALB	Ind. Median
Current Ratio	5.85●	—	1.43	1.21	5.90
Debt/Equity	42.7%	—	112.3%	1.2%●	10.9%
NetDebt/EBITDA	0.83●	—	13.13	0.90	1.15

Profitability
Metric	FATE	MSB	TLX	RTALB	Ind. Median
Net Margin	-2,056.8%	-115.3%	-0.9%	136.3%●	-125.7%
ROE	-55.5%	-11.3%	-1.8%	15.1%●	-47.5%
ROA	-38.0%	-8.6%	-0.7%	13.1%●	-35.8%
EBITDA Margin	-1,859.1%	-76.6%	3.0%	9.0%●	-105.8%

Growth + Dividend
Metric	FATE	MSB	TLX	RTALB	Ind. Median
Rev. Growth	-52.6%	410.4%●	56.3%	24.0%	5.1%
NI Growth	—	—	—	134.0%	12.1%
Div. Yield	—	0.0%●	—	0.0%●	0.2%
Payout	—	0.0%	—	0.0%	0.0%

Valuation
Metric	FATE	LCTX	EDIT	CABA	FHTX	VNDA	Ind. Median
P/E	—	—	—	—	—	—	17.91
P/B	1.95	6.54	81.05	3.46	-4.82●	1.32	3.51
EV/EBITDA	—	—	—	—	—	—	14.82
P/S	55.49	23.86	9.23	—	13.06	1.70●	10.89

Financial Health
Metric	FATE	LCTX	EDIT	CABA	FHTX	VNDA	Ind. Median
Current Ratio	5.85	6.89●	3.22	2.95	2.92	2.16	5.90
Debt/Equity	42.7%	4.4%	1,632.8%	25.6%	-55.0%●	4.7%	10.9%
NetDebt/EBITDA	0.83	1.18	0.52●	0.53	1.97	1.39	1.15

Profitability
Metric	FATE	LCTX	EDIT	CABA	FHTX	VNDA	Ind. Median
Net Margin	-2,056.8%	-434.4%	-281.6%	—	-266.9%	-110.0%●	-125.7%
ROE	-55.5%●	-96.6%	-326.1%	-156.0%	—	-60.5%	-47.5%
ROA	-38.0%	-58.0%	-52.8%	-112.0%	-31.3%●	-45.0%	-35.8%
EBITDA Margin	-1,859.1%	-291.9%	-258.7%	—	-257.0%	-62.6%●	-105.8%

Growth + Dividend
Metric	FATE	LCTX	EDIT	CABA	FHTX	VNDA	Ind. Median
Rev. Growth	-52.6%	54.6%●	8.0%	-100.0%	20.1%	8.2%	5.1%
NI Growth	—	—	—	—	—	—	12.1%
Div. Yield	—	—	—	—	—	—	0.2%
Payout	—	—	—	—	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on FATE

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.